¬üªF®É¶¡2¤ë15¤é¡A¬ü°ê±M§Q°Ó¼Ð§½±M§Q¼f§Pº[¶DÄ@©eû·|(Patent Trial and Appeal Board¡APTAB) §@¥XµôƒK¡A§P©w±i¾W¤Î¨ä¬ü°ê³Â¬Ù²z¤u¾Ç°|Broad¬ã¨s¾÷ºc©Ò¥Ó½ÐªºCRISPR-Cas9°ò¦]½s¿è±M§Q¡A»P¥[¦{¤j¾Ç§B§J§Q¤À®ÕJennifer Doudna¹Î¶¤ªºCRISPR¬ãµo¦¨ªG¡A¨Ã¤£¦s¦b½Ä¬ð (no interference in fact)¡A¦]¦¹±i¾W¹Î¶¤¥i¥H«O¦³¨ä±M§Q¡C¦¹µôƒKÅý³o¤@³õ¤Ñ»ùªº±M§Qª§¹Ü¾Ô¼È§i¸¨¹õ¡A±i¾W¹Î¶¤§¹³Ó¡CµM¦Ó¡A³oÀ³¸Ó¥u¬O¥ð¤î²Å¦Ó¤£¬O¥yÂI¡ADoudna¹Î¶¤¹ï§P¨Mµ²ªGªí¥Ü¿ò¾Ñ¡A¤]¤£±Æ°£¤W¶D¦Ü¬ü°êÁp¨¹¨µ°j¤W¶Dªk°|ªº¥i¯à¡C
³o³õ§ñÃö°ò¦]½s¿èÃöÁä§Þ³Nªº¤Ñ»ù±M§Q¾Ôn±q2012¦~»¡°_¡C¦b2012¦~ªº®ÉÔ¡A¥ô¾¥[¦{¤j¾Ç§B§J§Q¤À®ÕJennifer Doudna©M¦oªº¦P¨ÆEmmanuelle Charpentierµoªí½×¤å¡A²v¥ý³ø¹DCRISPR³o¤@°ò¦]½s¿è¨t²Î¡A¯àƒú¦b¸ÕºÞ¤¤ºë½T¤Á³ÎDNA¡C¯àºë½T¤Á³ÎDNAªº§Þ³N¥Î³~«Ü¦h¡A¨Ò¦pµo²{¤@¨Ç¦]°ò¦]°ÝÃD¤Þ°_ªº¯fÅܮɡA«K¥i¥H¨Ï¥Î°ò¦]Àøªk¡A§â¸Ó¬q¦³°ÝÃDªº°ò¦]°ÅÂ_¡A¦A¸É¤W¥¿±`ªº°ò¦]¡CDoudna©MCharpentier¹Î¶¤´£¥X¤F¬ð¯}©Êªº³Ð·s§Þ³N¡A°£¤F¤Þ°_°ª«×Ãöª`¥~¡A¤]¦]¦¹Àò±o³\¦h¼ú¶µ¡C
¨ì¤F2013¦~1¤ë¡A¦b¬ü°ê³Â¬Ù²z¤u¾Ç°|¥ô¾ªº±i¾W»P¨ä¹Î¶¤¡A¤]µoªí½×¤å¡A¤¶²Ð¦p¦ó±NCRISPR°ò¦]½s¿è§Þ³NÀ³¥Î¦b´Óª«¡B°Êª«¡B»P¤HÃþ²ÓM¤W¡C¦ÓCRISPR-Cas9±M§Qªºª§¹Üªº®Ö¤ß«h¦b©ó½ÖÀ³¸ÓÀò±oCRISPR¦b´Óª«»P°Êª«¤¤¨Ï¥Îªº±M§QÅv¡CDoudna¹Î¶¤¬OCRISPR°ò¦]½s¿è§Þ³Nªº²Ä¤@µo©ú¤H¡A±i¾W¹Î¶¤«o¬O²Ä¤@Ó´£¥X±NCRISPR-Cas9±M§Q¥Î©ó¤HÃþ°ò¦]Àøªk¡B°òÂà§@ª«¡B¥H¤Î°ò¦]¤uµ{°Êª«ªºµo©ú¤H¡C
¦]¦¹¥[¦{¤j¾Ç§B§J§Q¤À®Õ¦VPTAB´£¥X½Æ¼fn¨D¡A¬D¾Ô±i¾W»P¨äBroad ¬ã¨s¾÷ºcªº¤Q¦h¶µCRISPR°ò¦]½s¿è±M§Q¡C¦Ó§@¬°³Q§iªºBroad ¬ã¨s¾÷ºc«h»{¬°¡A¨ä±M§Q»PDoudna¹ÎÅ餧CRISPR±M§Q¡A ¨âªÌ¡u¨Ã¤£½Ä¬ð¡v¡]no interference¡^¡A¤]´N¬O»¡¡A¨âªÌªº¬ã¨sµo²{¨Ã¨S¦³«ÂСC
¦b2¤ë15¤éªºµôƒK¤¤¡APTAB¥u¥Î¤F¤@¥y¸Ü´N§@¥X§P¨M¡G¡y¨Æ¹ê¤W¨Ã¤£½Ä¬ð¡z(no interference in fact)¡CPTABªºªk©x̧P©w¦b±i¾W¤§«e¡A¨S¦³¬ã¨s¤Hû¯àƒúµ´¹ï½T»{CRISPR§Þ³N¯àÀ³¥Î©ó¦³®Ö²ÓM¡A¦p¤HÃþ²ÓM¡A¦]¦¹ªk©x»{¬°±i¾Wªºµo©ú¨Ã«D²³æªºÂX®i©µ¦ù©Î¬O§ï¨}¡A¦Ó¬O¨ã¦³³Ð·s©Ê¡A¦]¦¹§P©w±i¾W¹Î¶¤±o¥H«O¯d¨ä±M§Q¡C
¦bÀò±xµôƒK«á¡A¥[¤j§B§J§Q¤À®ÕµoªíÁn©ú¡Aªí¥Ü´L«ªk©x§P¨M¡A¦ý¦P®É¤]°íºÙ¬ODougna»PCharpentier¹Î¶¤º¥ýµo©úCRISPR°ò¦]½s¿è§Þ³N¤Î¨äÀ³¥Î¡B¨Ã¦P®É¬O²Ä¤@Ó±N¦¹¬ã¨sµo²{¤½¶}¤Î¥Ó½Ð±M§Qªº¡C¦]¦¹¡A¥[¦{¤j¾Ç·|¼f·Vµû¦ô¤U¤@¨Bªºªk«ß¦æ°Ê¡A¥]¬A¤W¶Dªº¥i¯à©Ê¡G¡uWe continue to maintain that the evidence overwhelmingly supports our position that the Doudna¡þCharpentier team was the first group to invent this technology for use in all settings and all cell types, and was the first to publish and file patent applications directed toward that invention, and that the Broad Institute¡¦s patents directed toward use of the CRISPR-Cas9 system in particular cell types are not patentably distinct from the Doudna¡þCharpentier invention. For that reason, UC will carefully consider all options for possible next steps in this legal process, including the possibility of an appeal of the PTAB¡¦s decision.¡v
¤@¯ë¬ã§PDougna»PCharpentier¹Î¶¤¤£·|¦]¦¹½}¥ð¡A¥[¦{¤j¾Ç¦³«Ü¤j¾÷·|·|¤W¶D¦Ü¬ü°êÁp¨¹¨µ°j¤W¶Dªk°|¡A¦Ó±µ¤U¨Óªº¼fij©MµôƒK¡A¤]·|«ùÄò¤@¬q®É¶¡¡A¦ý¦Ü¤Ö¥Ø«e¬°¤î¡A±i¾W¹Î¶¤Àò±o¤F¼È®Éªº³Ó§Q¡C
¨´¤µúd¤î¡AUSPTO¤w¸g±Â¤©50¦h¥ó»PCRISPR¦³Ãöªº±M§Q¡A¨ä¤¤Broad¬ã¨s¾÷ºc©M¬ü°ê³Â¬Ù²z¤u¾Ç°|¦@¾Ö¦³15¥ó¡CBroadªí¥Ü¡A¬ì¬ã¤Hû³£¥i¥H¥Î¥L̪º§Þ³N°µ¾Ç³N¬ã¨s¡A¦ý¦pªG¬O¼t°Ó¨Ï¥Î«h¥²¶·¥I¶O±ÂÅv¡C¹³Editas Medicine«K¾Ö¦³¨ä¤¤¤@¶µBroad¬ã¨s¾÷ºcCRISPR±M§Qªº¿W®a¨Ï¥ÎÅv¡A¦]¦¹¡AEditas Medicine¤]ªá¤F¤£¤Ö¿ú¨ó§UBroad¬ã¨s¾÷ºcÀ³¥I¨ä©Ò±Á{ªºªk«ß¬D¾Ô¡C
±i¾W¸ÑÄÀCRISPR°ò¦]½s¿è§Þ³N¦p¦ó¹B§@
¡i³¾Àý¥þ²y±M§Q§G§½¡j±M§QºÊ´úªA°È§Y¤é°_¬°±z¶}³ÐP³Ó¥ý¾÷¡I